Chitomur®
Distribution of patients by nosological forms and age. Table 1
Diagnosis Age Number of Patients
Control Group Primary Group
Benign prostatic hyperplasia 45-62
Overactive bladder 48-56 9 22
Total: 19 40
* p <0.05 - significant compared to the indicator before treatment.
In addition to conventional means, patients of the primary groups (18 men and 22 women) were pre-
scribed CHITOMUR® 1 capsule 2 times a day with meals for 30 days. Patients in the control groups
(10 men and 9 women) received only conventional treatment. The distribution of patients by groups
is shown in Table 1.
The effectiveness of the use of CHITOMUR®was assessed based on the dynamics of complaints of
patients, general clinical examination of blood and urine, the biochemical study of blood, the degree
of abdominal pressure during urination, and the nature of the urine stream, fluorometric index.
RESEARCH RESULTS
The results of a clinical study of CHITOMUR® showed that pollakiuria (increased frequency of uri-
nation) altogether ceased to bother 88.3% of patients with BPH. In 93.2% of patients, the need for
nocturnal urination disappeared. Stranguria (difficulty urinating) ceased to bother 74.8% of patients,
26.7% of patients noted an increase in the urine stream and relief during the act of urination.
The dynamics of the study results in patients with BPH before and after the course of treatment with
CHITOMUR® is presented in Table 2.
Influence of CHITOMUR® on the state of urodynamics in patients Table 2
with benign prostatic hyperplasia.
Indicator Before After Treatment with Conventional After Treatment with
Treatment Methods Chitomur®
Time of urinary retention 4,5±0,6 3,4±0,4* 2,2±0,3*
Number of urinations:
- in the daytime 8,7±0,2 7,2±0,3* 6,3±0,1*
- in nighttime 3,7±0,3 2,9+0,2 2,0+0,4
Abdominal pressure, (points) 3,2 2,7 2,3
The nature of the stream of urine, (points) 3,4 2,5* 2,2*
Average urination rate, (ml/s) 13,5±1,3 15,1±1,6 19,4±1,4*
Maximum speed of urination, (ml/s) 17,2±1,8 19,1±1,5 21,4±1,6
Maximum speed of urination, (ml/s) 6,4±0,1 5,4±0,2* 4,4±0,4*
* p <0.05 - significant compared to the indicator before treatment.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.